MARKET

VIVO

VIVO

Meridian Bioscience Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

25.37
+0.74
+3.00%
After Hours: 25.37 0 0.00% 16:29 05/17 EDT
OPEN
25.00
PREV CLOSE
24.63
HIGH
25.42
LOW
24.84
VOLUME
237.05K
TURNOVER
0
52 WEEK HIGH
28.72
52 WEEK LOW
17.00
MARKET CAP
1.11B
P/E (TTM)
17.94
1D
5D
1M
3M
1Y
5Y
Marijuana Stock Movers For May 9, 2022
GAINERS: Item 9 Labs (OTC:INLB) shares closed up 9.00% at $1.09
Benzinga · 05/09 20:48
Meridian Bioscience's Q2 Revenues Increase 30% To $111M, Highest In Company History
Benzinga · 05/06 19:10
Meridian Bioscience (VIVO) Q2 Earnings and Revenues Surpass Estimates
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 37.50% and 11.73%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/06 13:15
Meridian Bioscience: Q2 Earnings Insights
  Meridian Bioscience (NASDAQ:VIVO) reported its Q2 earnings results on Friday, May 6, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/06 13:08
BRIEF-Meridian Bioscience Reports Record Second Quarter Fiscal 2022 Operating Results
reuters.com · 05/06 12:22
Meridian Bioscience Q2 EPS $0.66 Beats $0.47 Estimate, Sales $111.23M Beat $99.54M Estimate
Meridian Bioscience (NASDAQ:VIVO) reported quarterly earnings of $0.66 per share which beat the analyst consensus estimate of $0.47 by 40.43 percent. This is a 17.86 percent increase over earnings of $0.56 per share from
Benzinga · 05/06 12:19
-- Earnings Flash (VIVO) MERIDIAN BIOSCIENCE Reports Q2 EPS $0.66
MT Newswires · 05/06 08:09
Meridian Bioscience's Earnings: A Preview
Meridian Bioscience (NASDAQ:VIVO) is set to give its latest quarterly earnings report on Friday, 2022-05-06. Here's what investors need to know before the announcement. Analysts estimate that Meridian Bioscience will report an earnings per share (EPS) of $...
Benzinga · 05/05 17:22
More
No Data
Learn about the latest financial forecast of VIVO. Analyze the recent business situations of Meridian Bioscience Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average VIVO stock price target is 30.00 with a high estimate of 30.00 and a low estimate of 30.00.
High30.00
Average30.00
Low30.00
Current 25.37
EPS
Actual
Estimate
0.170.330.490.66
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 278
Institutional Holdings: 48.41M
% Owned: 111.10%
Shares Outstanding: 43.58M
TypeInstitutionsShares
Increased
49
2.11M
New
27
1.93M
Decreased
67
2.94M
Sold Out
27
1.00M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+2.93%
Healthcare Equipment & Supplies
+2.38%
Key Executives
Chairman/Director
John McIlwraith
Chief Executive Officer/Director
John Kenny
Chief Financial Officer/Executive Vice President
Andrew Kitzmiller
Executive Vice President
Tony Serafini-Lamanna
Executive Vice President
Lourdes Weltzien
Chief Accounting Officer
Julie Smith
Independent Director
James Anderson
Independent Director
Anthony Bihl
Independent Director
Dwight Ellingwood
Independent Director
John Rice
Independent Director
Catherine Sazdanoff
Independent Director
Felicia Williams
No Data
No Data
About VIVO
Meridian Bioscience, Inc. is a life science company. The Company is engaged in the development, manufacture, sale and distribution of diagnostic test kits, primarily for certain gastrointestinal and respiratory infectious diseases and elevated blood lead levels. The Company's segments include Diagnostics and Life Science. The Diagnostics segment consists of manufacturing operations for infectious disease products in Cincinnati, Ohio; Quebec City, Canada; and Modi' in, Israel. The segment also includes blood chemistry products in Billerica, Massachusetts and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; and Luckenwalde, Germany; and the sale and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, and bioresearch reagents domestically and abroad.

Webull offers kinds of Meridian Bioscience, Inc. stock information, including NASDAQ:VIVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIVO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VIVO stock methods without spending real money on the virtual paper trading platform.